Avita Medical stock pullback creates buying opportunity, says Northland

Northland tells investors in a research note that the 20% pullback in Avita Medical’s (RCEL) stock creates a buying opportunity. Reimbursement uncertainty that limited FY25 growth to 11% has eased, with six of seven MACs publishing rates, setting the stage for a potential return to a 20%+ topline growth trajectory, the firm says. Northland has an Outperform rating and $10 price target on Avita Medical shares.